Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 3

1(33.3%)

3Total

N/A(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04414111Active Not Recruiting

Highly Suppressive Treg in Delayed and Slow Graft Function After Kidney Transplantation

Role: collaborator

NCT06153641Active Not Recruiting

Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients

Role: collaborator

NCT04483102Not ApplicableActive Not Recruiting

RESTORE Declined Livers Study

Role: collaborator

NCT05656261Recruiting

APOL1 Genetic Testing in African Americans

Role: collaborator

NCT04415658Phase 3Completed

Intravenous Thyroxine for Heart-Eligible Organ Donors

Role: collaborator

NCT03837522Not ApplicableCompleted

Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies

Role: collaborator

All 6 trials loaded